Search hospitals > Missouri > Saint Louis
Siteman Cancer Center-South County
Claim this profileSaint Louis, Missouri 63129
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Tumors
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
244 reported clinical trials
52 medical researchers
Summary
Siteman Cancer Center-South County is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lung Cancer, Adenocarcinoma and other specialties. Siteman Cancer Center-South County is involved with conducting 244 clinical trials across 414 conditions. There are 52 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, and Hyun Kim.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Robert J. HayashiWashington University School of Medicine7 years of reported clinical research
Expert in Tumors
Expert in Lymphoma
58 reported clinical trials
110 drugs studied
Brian A Van Tine, M.D., Ph.D.Washington University School of Medicine2 years of reported clinical research
Expert in Sarcoma
Expert in Soft Tissue Sarcoma
47 reported clinical trials
64 drugs studied
Douglas R. AdkinsWashington University School of Medicine5 years of reported clinical research
Expert in Squamous Cell Carcinoma
Expert in Cancer
33 reported clinical trials
57 drugs studied
Hyun KimWashington University School of Medicine3 years of reported clinical research
Studies Pulmonary Fibrosis
Studies Fibrosis
30 reported clinical trials
42 drugs studied
Clinical Trials running at Siteman Cancer Center-South County
Gastroesophageal Junction Adenocarcinoma
Prostate Cancer
Esophageal Adenocarcinoma
Breast Cancer
Cancer
Esophageal Carcinoma
Colorectal Cancer
Lung Cancer
Gastric Cancer
Non-Small Cell Lung Cancer
Proton Therapy vs Photon Radiation
for Esophageal Cancer
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in treating patients with esophageal cancer.
Recruiting2 awards Phase 31 criteria
Atezolizumab + Chemotherapy
for Stomach and Esophageal Cancer
This phase II trial compares atezolizumab in combination with chemotherapy (docetaxel, oxaliplatin, leucovorin calcium, fluorouracil, capecitabine) to atezolizumab alone for controlling the growth and/or spreading of the disease in patients with gastric or gastroesophageal junction (JEG) cancer that has not spread from where it first started (local) or only has spread to nearby lymph nodes or tissue (locoregional) and has high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). The mismatch repair (MMR) system in the body corrects errors made during the copying of DNA and serves as a proofreading function. If this system isn't working correctly, mutations (changes) in DNA occur which can allow the cancer to grow or spread. This is called dMMR (deficient mismatch repair) . MSI-H describes cancer cells that have a high number of mutations within microsatellites. For example, microsatellite testing that shows mutations in 30% or more microsatellites is called microsatellite instability-high (MSI-H). Microsatellites are short, repeated sequences of DNA. There is evidence that MSI-H/ dMMR gastric or GEJ tumors respond well to immunotherapy. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill tumor cells. Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Chemotherapy drugs such as leucovorin calcium and fluorouracil work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using atezolizumab as immunotherapy with and following chemotherapy versus atezolizumab alone prior to and after surgery may shrink or stabilize the tumor in patients with MSI-H/dMMR localized gastric or GEJ cancer and may increase the length of time after treatment that cancer does not come back or get worse.
Recruiting1 award Phase 2
Ceralasertib + Trastuzumab Deruxtecan
for Solid Tumors
The dose escalation phase of this trial identifies the safety, side effects and best dose of ceralasertib (AZD6738) when given in combination with trastuzumab deruxtecan (DS-8201a) in treating patients with solid tumors that have a change (mutation) in the HER2 gene or protein and have spread to other places in the body (advanced). The dose expansion phase (phase Ib) of this trial compares how colorectal and gastroesophageal cancers with HER2 mutation respond to treatment with a combination of ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone. Ceralasertib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. Ceralasertib and trastuzumab deruxtecan may be safe, tolerable and effective in treating patients with advanced solid tumors expressing the HER2 protein or gene.
Recruiting1 award Phase 126 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Siteman Cancer Center-South County?
Siteman Cancer Center-South County is a medical facility located in Saint Louis, Missouri. This center is recognized for care of Cancer, Breast Cancer, Tumors, Lung Cancer, Adenocarcinoma and other specialties. Siteman Cancer Center-South County is involved with conducting 244 clinical trials across 414 conditions. There are 52 research doctors associated with this hospital, such as Robert J. Hayashi, Brian A Van Tine, M.D., Ph.D., Douglas R. Adkins, and Hyun Kim.